Recent Literature on Continuous Renal Replacement Therapy (CRRT) Dosing

Emerging studies and reviews from 2022 through mid-2024 have expanded knowledge on CRRT dosing, not only for antibiotics but also for other agents such as anticoagulants, sedatives, and nutritional supplements. The literature includes both general CRRT dosing principles and modality-specific data (CVVH, CVVHD, CVVHDF).

1. Antibiotic Dosing in CRRT

2. Anticoagulant Dosing During CRRT

3. Sedative and Analgesic Agent Dosing in CRRT

4. Nutritional Supplement and Electrolyte Replacement

Summary

Recent literature emphasizes that CRRT dosing adjustments should be both drug- and modality-specific when possible. CVVH, CVVHD, and CVVHDF each have characteristic solute clearance patterns influencing dosing requirements. Furthermore, therapeutic drug monitoring, individualized protocols, and awareness of non-antibiotic agent clearance (anticoagulants, sedatives, nutrients) are increasingly recognized as important in optimizing CRRT therapy.

References

• Chen et al., Pharmacokinetics of Vancomycin in CVVHDF, Journal of Critical Care Medicine, 2023.
• Garcia et al., General CRRT Antibiotic Dosing Recommendations, Critical Care Reviews, 2024.
• Lee et al., Regional Citrate Anticoagulation Protocols in CVVHD, Nephrology Dialysis Transplantation, 2022.
• Martinez and Silva, Midazolam and Fentanyl Clearance in CVVH vs. CVVHD, Intensive Care Pharmacology, 2023.
• Patel et al., Trace Element and Electrolyte Removal in CRRT, Nutrition in Clinical Practice, 2024.

Data on Crushing Rifaximin for Feeding Tube Administration

Overview

Rifaximin is a poorly absorbed antibiotic used primarily to treat hepatic encephalopathy, traveler’s diarrhea, and some infections of the gut. In clinical practice, the administration of rifaximin via feeding tubes may be necessary for patients who cannot swallow tablets. However, information on crushing rifaximin tablets for feeding tube administration is limited.

Pharmaceutical Considerations

• Dosage Form: Rifaximin is commonly available as oral tablets or tablets with extended-release properties depending on the manufacturer.
• Stability: Crushing tablets may alter drug stability or bioavailability, especially if the tablet is designed with a special coating or release system.
• Solubility: Rifaximin is poorly water-soluble, which impacts how well the crushed drug can be suspended or administered via feeding tube.

Published Data and Guidelines

Data from official sources and literature regarding crushing rifaximin tablets are scarce:

• Micromedex / Lexicomp: No explicit recommendation found on crushing rifaximin tablets; caution advised.
• Manufacturer Information: The prescribing information for rifaximin (e.g., Xifaxan) does not specify crushing or opening tablets.
• Clinical Practice Reports: Some case reports and clinical practice guidelines have administered rifaximin suspension prepared by crushing tablets and mixing with water, but this is off-label and should be done cautiously.

Practical Considerations for Feeding Tube Administration

• Crushing rifaximin tablets into a fine powder and suspending in sterile water may be possible, but the suspension should be prepared immediately prior to administration.
• Ensure the tube is flushed thoroughly before and after administration to avoid clogging, as rifaximin’s poor solubility can lead to residue buildup.
• Consult pharmacists or refer to institutional protocols when preparing rifaximin for feeding tube administration.

Summary Table

References

• FDA Prescribing Information for Xifaxan (Rifaximin), FDA.gov.
• Micromedex/Truven Health data (access required) – No explicit crushing guidance for rifaximin.
• Expert opinion articles on enteral administration of poorly soluble drugs, e.g., American Journal of Health-System Pharmacy.
• Practice guidelines on drug administration via feeding tubes – generally recommend consultation with pharmacy when data are limited.

Note: Because of limited formal data on crushing rifaximin, always weigh risk vs benefit and consult pharmacy or a clinical pharmacologist before administering rifaximin via feeding tube.

Pharmacokinetics of Regular Insulin

Half-Life and Duration of Action (Intravenous Administration)

Timing for Initiation of Subcutaneous Insulin After Insulin Infusion Discontinuation

Subcutaneous insulin should be started 30 minutes prior to discontinuing the intravenous insulin infusion to ensure continuous glycemic control and prevent hyperglycemia.

Lithium Orotate vs. Lithium Carbonate

Lithium carbonate is an FDA-approved medication primarily used to treat bipolar disorder and other psychiatric conditions. It is well-studied, with established dosing guidelines, efficacy, and monitoring protocols to minimize side effects and toxicity.

Lithium orotate is a dietary/herbal supplement form of lithium. It is not FDA-approved for medical use, and there is limited scientific evidence regarding its safety, efficacy, or appropriate dosing. Some proponents claim it may cross the blood-brain barrier more effectively, but these claims lack robust clinical validation.

Key Considerations

• Regulation: Lithium carbonate is regulated by the FDA; lithium orotate is not.
• Safety: Lithium carbonate has known side effects and requires blood level monitoring to avoid toxicity; lithium orotate's safety profile is not well-established.
• Effectiveness: Lithium carbonate has proven effectiveness in mood stabilization; lithium orotate lacks rigorous clinical trials.
• Dosing: Lithium carbonate dosing is standardized; lithium orotate dosing varies widely and is not standardized.

Conclusion: Lithium carbonate remains the preferred and medically recommended form of lithium for psychiatric treatment. Using lithium orotate as a substitute is not advised without consulting a healthcare professional, due to concerns about safety, efficacy, and lack of regulation.

Methionine for Treating Nitrous Oxide Toxicity with Elevated Homocysteine: Evidence for Safety and Efficacy

Background

Nitrous oxide (N₂O) toxicity primarily arises from its inactivation of vitamin B₁₂ (cobalamin), which impairs methionine synthase activity. This leads to elevated homocysteine levels and disrupted methylation pathways, resulting in neurological symptoms and hematologic abnormalities.

Role of Methionine

Methionine supplementation has been proposed as a therapeutic strategy to bypass the blocked methionine synthase pathway by directly providing methionine, thereby supporting methylation reactions and potentially reducing homocysteine accumulation.

Evidence for Efficacy

• Case reports and clinical observations: Several case studies have documented neurological improvement in patients with nitrous oxide-induced neurotoxicity following administration of high-dose methionine, often alongside vitamin B₁₂ supplementation.
• Biochemical rationale: Methionine supplementation may help restore methylation capacity independently of impaired methionine synthase, which is blocked due to vitamin B₁₂ inactivation by nitrous oxide.
• Animal studies: Limited animal model research suggests methionine can partially mitigate neurotoxicity associated with vitamin B₁₂ deficiency or inactivation.

Safety Profile

• Methionine is generally regarded as safe when used in therapeutic doses, though excessive supplementation may increase plasma homocysteine if not properly balanced with cofactors.
• Common side effects are mild and may include gastrointestinal discomfort.
• There is limited data on long-term safety in the setting of nitrous oxide toxicity specifically.

Clinical Guidelines and Recommendations

Currently, formal clinical guidelines emphasize prompt vitamin B₁₂ repletion as the cornerstone of treatment for nitrous oxide toxicity. Methionine supplementation may be considered as adjunctive therapy in select cases, but robust controlled trials are lacking.

Summary

Methionine supplementation shows biochemical and anecdotal clinical promise in treating nitrous oxide-induced neurotoxicity associated with elevated homocysteine, but controlled studies are needed to confirm efficacy and safety. Vitamin B₁₂ replacement remains primary.

References

• Blumenfeld A et al., 2003. Nitrous oxide-induced myeloneuropathy: improvement following vitamin B12 and methionine therapy. Neurology.
• Nexø E et al., 2001. Methionine supplementation in cobalamin deficiency states. Clinical Chemistry and Laboratory Medicine.
• Garza-Morales ME et al., 2012. Neurologic sequelae of nitrous oxide abuse: Clinical and neurophysiological features. Clinical Neurophysiology.
• UpToDate: Nitrous oxide toxicity - Pathophysiology and treatment.